Precious Metals Chemistry is a constantly evolving business unit. And we are happy to inform you here on our most important changes and novelties.
Please feel free to contact us for more information!
March 20, 2019 - API customers celebrate CPhI Japan's success at Argentinean Embassy in Tokyo
Umicore Precious Metals Chemistry and the Ambassador of the Republic of Argentina in Japan invited Umicore’s Japanese API clients to celebrate CPhI Japan and their successful collaboration. Umicore PMC supplies to the strongly regulated Japanese market platinum- and gold-based APIs and intermediates manufactured out of Umicore’s Argentina API plant.
The evening event was held at the Argentinean Embassy in Tokyo and enjoyed a great atmosphere just after CPhI Japan. About 30 leaders of Umicore’s main API clients were welcomed by Ambassador Alan Beraud, Umicore Argentina’s President Claudio Escobar, and Umicore’s Director of Global API Business Michael Schwarz.
In a relaxed atmosphere the attendees could network and exchange thoughts and information on the API business in Japan. The event contributed to strengthening the close and trustworthy relationship Umicore has built with its Japanese Customers and its trade partner Kaneda.
February 13, 2019 - Umicore supports pediatric oncology at German Würzburg university clinic
Umicore Precious Metals Chemistry donated again today EUR 2,500.00 to support the Parents Initiative of the university clinic of Würzburg for children suffering from cancer diseases. This donation will contribute to the efforts of this non-profit organisation to support in their daily lifes families of children and adolescents suffering from cancer. It will also contribute to finance the research of the university on stem cell transplantation and brain tumors.
Umicore is a leading manufacturer of active pharmaceutical ingredients used as chemotherapeutics and has been regularly supporting this Initiative that provides psychologic support, logistic help and much more to sick children and their families.
December 17, 2018 - Umicore expands production capacity for fuel cell catalysts
Umicore announced today that it will be expanding its production capacity for fuel cell catalysts in South-Korea to support the growth of Hyundai Motors Group as well as other automotive customers.
The low double-digit million euro investment entails the construction of a new production plant close to Umicore’s technology development centre near Seoul. The new plant will be commissioned towards the end of 2019 and is expected to be fully ramped up by the end of 2020. The selected site allows for further expansions beyond 2020. With this production footprint expansion in South-Korea and the existing production capacity in Hanau, Germany, Umicore is well placed to serve the growing demand from its automotive customers globally.
In the move to cleaner mobility, fuel cell drivetrains are gaining traction as an environmentally friendly alternative to combustion engines, with the technology maturity now demonstrated and commercial scale programs being launched by several car OEMs.
Umicore has developed a complete and competitive portfolio of product technologies for fuel cell catalysts and has entered into close collaboration agreements with leading OEMs for existing car platforms as well as future development programs.
Pascal Reymondet, EVP Catalysis, commented: "Today’s announcement underlines Umicore’s commitment to further strengthen its unique position in the technology portfolio and roadmap for clean mobility materials, being the only company worldwide offering at commercial scale the full spectrum of materials technologies to drive the transition to cleaner mobility."
October 4, 2018 - Umicore Argentina further improves its quality systems after successful FDA audit
Umicore Argentina plant, which produces a series of anti-cancer active pharmaceutical ingredients, was successfully audited for the second time by the US Food and Drug Administration (FDA) in May 2018. The auditor concluded that the plant was run according the FDA standards and the plant remained FDA approved. The auditor only mentioned in his 483 report (official FDA audit report) four points to be improved in the quality systems of the plant. No warning letter was issued by the FDA.
These comments have been taken seriously and adjustments have been implemented. The quality of the products we manufacture and the maximum safety of the patients being treated with the final drugs produced out of our active pharmaceutical ingredients remain our constant focus and the improvements recommended by the FDA Auditor contribute to bring them to an even higher level.
The areas of improvements relate to incorrect or incorrectly applied control procedures or equipment used at early stage of the manufacturing process as well as to the area of microbiology where a better training of existing procedures will improve our quality system. The inspector furthermore identified the opportunity to improve laboratory records.
Final quality controls of the manufactured active pharmaceutical ingredients have proven that their safety and quality have always remained at highest required level.
Please click here for more information on the 483 report and the comments of the FDA Auditor.
August 17, 2018 - Umicore expands cross coupling technology portfolio with Buchwald precatalysts
Umicore's business unit Precious Metals Chemistry, is proud to announce that it is expanding its existing cross coupling catalyst portfolio with Buchwald precatalysts after it licensed this technology from the Massachusetts Institute of Technology (MIT).
Buchwald’s catalyst technology is key to develop efficient cross-coupling reactions, one of the most elegant and versatile ways an organic chemist can develop sustainable chemical syntheses, be it for agrochemical, electronic, fine chemical or pharmaceutical applications.
Buchwald highly active precatalysts bear electron-rich and greatly tunable ligands and can be used in cross-coupling reactions for the formation of C-C, C–N, C–O, C–F, C–CF3, and C–S bonds. These air, moisture and thermally stable catalysts allow to significantly reduce catalyst loadings and reaction times; even very challenging cross coupling reactions are now achievable in highly efficient conditions. With most recently developed precatalysts, the catalytic active species can even be formed without any reducing agent, which leads to simpler and more efficient reactions.
Umicore now offers to its customers worldwide a comprehensive list of Buchwald precatalysts from research to commercial scale in high and consistent quality. And the non-exclusive license agreement with MIT enables Umicore to provide full access to a proprietary, patent-protected cutting-edge technology and to support its customers with a broader portfolio of homogeneous catalysts and service offering.
June 11, 2018 - Umicore succeeded second Food and Drug Administration audit at its Argentinean manufacturing site
Umicore’s Active Pharmaceutical Ingredients facility in Pilar, Buenos Aires, successfully passed its second cGMP (current Good Manufacturing Practice) audit by the US Food and Drug Administration (FDA) in May 2018. The Auditor acknowledged that both the production area and the associated documentation were well maintained, rewarding Umicore’s constant focus on the quality of its production processes and systems.
Umicore manufactures in Pilar cisplatin, carboplatin, oxaliplatin and arsenic trioxide: four oncology APIs produced for global markets according to the latest international guidelines. It additionally exclusively manufactures a few high potency APIs under customer contracts.
Umicore's state of the art facility in Pilar opened in 2009 and offers high quality products, professional services – such as exclusive development and synthesis and regulatory support or IP management and strategy. Umicore is committed to further develop the facility to ensure first class products and services to its global customers.
December 20, 2017 - Umicore to acquire Materia’s Metathesis catalyst business
Umicore announced today that it has reached an agreement to acquire Materia's metathesis catalyst business for an enterprise value of USD million 27.
Materia is a leader in metathesis with its unique proprietary technology developed by 2005 Chemistry Nobel Prize laureate Prof. Robert H. Grubbs, its broad portfolio of customized metathesis catalysts and its strong business position. Metathesis is a unique chemical technology that shortens the synthesis of complex pharmaceuticals, specialty chemicals and polymers and is increasingly used in the chemical industry.
Through this acquisition, Umicore will broaden its range of catalyst technologies, expand its homogeneous catalysts offer and gain access to an extended customer base. With the combined metathesis portfolios, Umicore will be able to provide its customers full access to proprietary, patent-protected cutting-edge technology. The combined businesses will continue to focus on innovation to allow customers to develop more efficient syntheses, produce more competitively and sustainably and keep or extend their leading positions in their own markets.
“The acquisition of Materia’s catalyst business is highly complementary with Umicore's Catalysis activities”, says Pascal Reymondet, Executive Vice President Catalysis, “and enables us to support our customers with a broader portfolio of homogeneous catalysts and service offering. To the technological expertise of Materia, we add the global, large-scale production capabilities and commitment of a global organization like Umicore, making the access, the industrial use and the success of this technology sustainable in the long term.”
The transaction is subject to closing conditions and is expected to be finalized in the first quarter of 2018.
July 10, 2017 - Umicore Hanau passed the TfS (Together for Sustainability) audit program
We are proud to announce the successfully audit of Umicore’s facility in Hanau (Germany) by the
Together for Sustainability (TfS) initiative. This confirms and reinforces Umicore’s policy and commitment to sustainability.
Volker Raab, Director Global HOC Business, comments:
“Due to our policy for sustainability, we passed the audit program of the 2011 founded TfS initiative without further ado.
We are very proud to be in accordance with the objectives of TfS and we look forward to the ongoing close collaboration with the participating group of companies.”
Our policy - Because we only have one environment…
We are committed to being a materials technology group providing our customers with the best solutions while making the smallest imprint manageable on the environment. We believe in the principles of sustainable development and willingly take on the responsibility that accompanies this commitment.
June 23, 2017 - Umicore inaugurates new production facility in Germany
Umicore’s business unit Precious Metals Chemistry inaugurated today its innovative production unit for advanced metal organic precursor technologies used in the semiconductor and LED markets, respectively TMGa (Trimethylgallium) and TEGa (Triethylgallium). The event was attended by European and overseas customers as well as local and regional politicians. The guest of honour was Dr. Barbara Hendricks, Germanys Federal Minister for the Environment, Nature Conservation, Building and Nuclear Safety.
Umicore’s TMGa manufacturing process is innovative and unique. It offers a more sustainable and ecological production method by minimizing hazardous side streams and material losses and optimizing yield to nearly 100%. This makes it superior to all existing manufacturing methods in the industry.
Dr Lothar Mussmann, Vice-President of Umicore Precious Metals Chemistry said “I am proud that this patented innovation has now become a world-class and industrial scale manufacturing plant. It will provide benefits for our customers and the environment and underlines Umicore’s position as a pioneer in sustainable technologies."
March 27, 2017 - Umicore’s Argentinian facility for anticancer APIs passes new European GMP audit
Umicore’s API (Active Pharmaceutical Ingredients) facility in Pilar, Buenos Aires, successfully underwent a European GMP (Good Manufacturing Practice) inspection by the German Health and Medicine Authority. The success of this new audit confirms Umicore ability to manufacture highly potent anticancer APIs at highest quality standards and to sell them in Europe.
Michael Schwarz, Director Global API Business, comments: “This is an important success for Umicore’s activities in highly potent anticancer APIs. It follows a number of successful inspections by international customers and health authorities and it shows that our manufacturing site has fully integrated the principles and guidelines of good manufacturing practices. This will strongly support our further growth in the European market.”
Umicore´s facility in Pilar opened in 2009 and manufactures cisplatin, carboplatin, oxaliplatin and arsenic(III) oxide for global markets, based on current international guidelines. It also exclusively produces a number of high quality proprietary highly potent APIs. Umicore’s API business offers professional services – such as exclusive hAPI development and manufacturing, IP and regulatory support, quality assurance and quality control – and highly competitive business terms. Umicore is committed to further develop the facility to be able to provide the first class products and services its global customers will need in future.
December 12, 2016 - Umicore rebranding is online
We are proud to announce the successful Go-Live of Umicore's new brand image and Precious Metals Chemistry's renewed website. Our customers and partners now benefit from even more online technical product and service information. Please contact us if you miss the information you are looking for.